Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

R1000600

Risperidone

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

R 64,766

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C23H27FN4O2
CAS Number:
106266-06-2
Molecular Weight:
410.48
MDL number:
MFCD00274576
UNSPSC Code:
41116107
PubChem Substance ID:
329823994
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

risperidone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

InChI key

RAPZEAPATHNIPO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

Looking for similar products? Visit Product Comparison Guide

General description

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Risperidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1604665

Risperidone System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1604654

Risperidone, United States Pharmacopeia (USP) Reference Standard

Y0000370

Risperidone for system suitability, European Pharmacopoeia (EP) Reference Standard

1604676

Risperidone Related Compounds Mixture, United States Pharmacopeia (USP) Reference Standard

Y0001276

Risperidone impurity K, European Pharmacopoeia (EP) Reference Standard

1604756

Risperidone Related Compound G, United States Pharmacopeia (USP) Reference Standard

BP1137

Risperidone, British Pharmacopoeia (BP) Reference Standard

BP1158

Risperidone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
Jérôme A J Becker et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)
The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))
Christian Spang Pedersen et al.
Behavioural brain research, 273, 63-72 (2014-07-30)
Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function). Whereas current medication ameliorates positive symptomatology, negative symptoms as well as cognitive
Yvonne Freund-Levi et al.
Dementia and geriatric cognitive disorders, 38(3-4), 234-244 (2014-06-28)
To examine the effects of galantamine and risperidone on agitation in patients with dementia. A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized
Andrea Fagiolini et al.
Expert opinion on pharmacotherapy, 11(10), 1727-1740 (2010-05-22)
It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service